NCT05208307View on ClinicalTrials.gov

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

PHASE2RecruitingINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

October 21, 2026

Study Completion Date

October 21, 2027

Conditions

Plasma Cell Myeloma

Interventions

BIOLOGICAL

Belantamab Mafodotin

Given IV

DRUG

Dexamethasone

Given PO

DRUG

Pomalidomide

Given PO

Trial Locations (1)

30322

RECRUITING

Emory University/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER

NCT05208307 - Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | Biotech Hunter | Biotech Hunter